《Mabs》雜志的最新年發(fā)文量為101篇。
這表明該刊在每年都會(huì)精選并發(fā)表一定數(shù)量的高質(zhì)量文章，以保持其在醫(yī)學(xué)：研究與實(shí)驗(yàn)領(lǐng)域的學(xué)術(shù)影響力。
該刊聚焦于醫(yī)學(xué)-醫(yī)學(xué)：研究與實(shí)驗(yàn)領(lǐng)域的前沿研究，致力于推動(dòng)該領(lǐng)域新技術(shù)和新知識(shí)的傳播與應(yīng)用。同時(shí)它積極鼓勵(lì)研究人員詳細(xì)發(fā)表其高質(zhì)量的實(shí)驗(yàn)研究和理論成果。
該刊的平均審稿周期約為 較慢,6-12周 。
Mabs 雜志發(fā)文統(tǒng)計(jì)
文章名稱(chēng)引用次數(shù)
- Antibodies to watch in 2019131
- Antibodies to watch in 201843
- The less-is-more in therapeutic antibodies: Afucosylated anti-cancer antibodies with enhanced antibody-dependent cellular cytotoxicity28
- Structure, heterogeneity and developability assessment of therapeutic antibodies26
- Ion channels as therapeutic antibody targets18
- Influence of N-glycosylation on effector functions and thermal stability of glycoengineered IgG1 monoclonal antibody with homogeneous glycoforms18
- Enabling adoption of 2D-NMR for the higher order structure assessment of monoclonal antibody therapeutics17
- Delivery of ALX-0171 by inhalation greatly reduces respiratory syncytial virus disease in newborn lambs16
- Deamidation and isomerization liability analysis of 131 clinical-stage antibodies16
- Challenges and new frontiers in analytical characterization of antibody-drug conjugates16
國(guó)家/地區(qū)發(fā)文量
- USA216
- GERMANY (FED REP GER)45
- England34
- Switzerland32
- CHINA MAINLAND27
- France26
- Canada16
- Netherlands15
- Belgium11
- Japan11
